HEALTH PROFESSIONAL · SOURCE READING

Accepted Risk-Adapted Treatment Strategies

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

Contemporary trials for pediatric Hodgkin lymphoma involve a risk-adapted, response-based treatment approach that titrates the length and intensity of chemotherapy and dose of radiation based on disease-related factors, including stage, number of involved nodal regions, tumor bulk, the presence of B symptoms, and early response to chemotherapy as determined by functional imaging. In addition, vulnerability related to age and sex is also considered in treatment planning.

Continue within this section

Classical Hodgkin lymphoma, low-risk disease →Classical Hodgkin lymphoma, intermediate-risk disease →Classical Hodgkin lymphoma, high-risk disease →NLPHL →

Preserved source evidence · Not medical advice